Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis

Abstract

Background A combination of programmed cell death protein‐1 (PD‐1)/programmed cell death ligand‐1 (PD‐L1) inhibitors and radiotherapy (RT) is increasingly being used to treat non‐small‐cell lung cancer (NSCLC). However, the safety and efficacy of this approach remains controversial. We performed a systematic review and meta‐analysis to summarize the related research. Methods We searched the China Biology Medicine, EMBASE, Cochrane Library, and PubMed databases for all the relevant studies. The Stata software, version 12.0 was used for the meta‐analysis. Results The study included 20 clinical trials that enrolled 2027 patients with NSCLC. Compared with non‐combination therapy, combination therapy using PD‐1/PD‐L1 inhibitors and RT was associated with prolonged overall survival (OS) (1‐year OS: odds ratio [OR] 1.77, 95% confidence interval [CI] 1.35–2.33, p = 0.000; 2‐year OS: OR 1.77, 95% CI 1.35–2.33, p = 0.000) and progression‐free survival (PFS) (0.5‐year PFS: OR 1.83, 95% CI 1.13–2.98, p = 0.014; 1‐year PFS: OR 2.09, 95% CI 1.29–3.38, p = 0.003; 2‐year PFS: OR 2.47, 95% CI 1.13–5.37, p = 0.023). Combination therapy also improved the objective response rate (OR 2.76, 95% CI 1.06–7.19, p = 0.038) and disease control rate (OR 1.80, 95% CI 1.21–2.68, p = 0.004). This meta‐analysis showed that compared with non‐combination therapy, combination therapy using PD‐1/PD‐L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3); however, this approach increased the rate of grade 1–2 immune‐related or radiation pneumonitis. Subgroup analyses revealed that the sequence of PD‐1/PD‐L1 inhibitors followed RT outperformed in which concurrent PD‐1/PD‐L1 inhibitor and RT followed PD‐1/PD‐L1 inhibitor. Combination of stereotactic body RT or stereotactic radiosurgery with PD‐1/PD‐L1 inhibitors may be more effective than a combination of conventional RT with PD‐1/PD‐L1 inhibitors in patients with advanced NSCLC. Conclusion Combination therapy using PD‐1/PD‐L1 inhibitors and RT may improve OS, PFS, and tumor response rates without an increase in serious adverse events in patients with advanced NSCLC. However, combination therapy was shown to increase the incidence of mild pneumonitis.

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination

“…The results of multivariable Cox proportional hazard regression analysis showed that the timing of TACE and drug combination therapy was an independent risk factor for OS and PFS. Previous studies have also shown that sequential use of immune checkpoint inhibitors after radiotherapy improves patient survival compared to concurrent use in other tumors [ 27 , 28 ]. Late combination had longer survival and progression-free survival compared to early combination, which may be due to the following reasons: (1) The tumor microenvironment in advanced HCC is in an immunosuppressed state, especially in patients with co-infection with chronic hepatitis B. T cells are dysfunctional.…”

Silencing of the lncRNA H19 enhances sensitivity to X-ray and carbon-ions through the miR-130a-3p /WNK3 signaling axis in NSCLC cells

“…Radiotherapy can be applied in all stages of disease. Our previous study showed that inspiring results were obtained with radiotherapy combined with immunotherapy [ 3 ]. However, radioresistance is acknowledged as a factor related to failure of cancer.…”

Combination strategies to maximize the benefits of cancer immunotherapy

“…So far, several clinical studies showed improved clinical outcomes when radiation is added to ICBs. In a meta-analysis including 20 clinical trials and 2,027 NSCLC patients, the combination of anti-PD1/PD-L1 inhibitors with radiotherapy was associated with significantly improved objective response rate (odds ratio [OR] 2.76, 95% CI 1.06–7.19, p = 0.038) and OS (2-year survival HR 1.77, 95% CI 1.35–2.33, p = 0.000) [ 85 ]. Currently, durvalumab has been approved as a maintenance therapy after platinum-based chemoradiation therapy for stage III NSCLC patients based on a Phase III PACIFIC trial [ 86 , 87 ].…”